Browsing Breast Cancer Research by author "Haider, Syed"
Now showing items 1-20 of 29
-
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; et al. (AMER ASSOC CANCER RESEARCH, 2021-02-15)Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ... -
Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse.
Turrell, FK; Orha, R; Guppy, NJ; Gillespie, A; Guelbert, M; et al. (NATURE PORTFOLIO, 2023-04-01)Patients with estrogen receptor (ER)-positive breast cancer are at risk of metastatic relapse for decades after primary tumor resection and treatment, a consequence of dormant disseminated tumor cells (DTCs) reawakening ... -
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Fitzpatrick, A; Iravani, M; Mills, A; Childs, L; Alaguthurai, T; et al. (AMER ASSOC CANCER RESEARCH, 2022-03-15)PURPOSE: Cerebrospinal fluid (CSF) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often necessitating repeated lumbar puncture to confirm or ... -
Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer.
Alexander, J; Mariani, O; Meaudre, C; Fuhrmann, L; Xiao, H; et al. (MDPI, 2022-01-07)Mutations and loss of E-cadherin protein expression define the vast majority of invasive lobular carcinomas. In a subset of these cases, the heterogeneous expression of E-cadherin is observed either as wild-type (strong ... -
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Baxter, JS; Brough, R; Krastev, DB; Song, F; Sridhar, S; et al. (WILEY, 2023-10-22)The F-box and WD repeat domain containing 7 (FBXW7) tumour suppressor gene encodes a substrate-recognition subunit of Skp, cullin, F-box (SCF)-containing complexes. The tumour-suppressive role of FBXW7 is ascribed to its ... -
Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade.
Jenkins, L; Jungwirth, U; Avgustinova, A; Iravani, M; Mills, A; et al. (AMER ASSOC CANCER RESEARCH, 2022-08-16)UNLABELLED: Immune-checkpoint blockade (ICB) promotes antitumor immune responses and can result in durable patient benefit. However, response rates in breast cancer patients remain modest, stimulating efforts to discover ... -
Capture Hi-C identifies putative target genes at 33 breast cancer risk loci.
Baxter, JS; Leavy, OC; Dryden, NH; Maguire, S; Johnson, N; et al. (NATURE PUBLISHING GROUP, 2018-03-12)Genome-wide association studies (GWAS) have identified approximately 100 breast cancer risk loci. Translating these findings into a greater understanding of the mechanisms that influence disease risk requires identification ... -
Characterisation of the Stromal Microenvironment in Lobular Breast Cancer.
Gómez-Cuadrado, L; Bullock, E; Mabruk, Z; Zhao, H; Souleimanova, M; et al. (MDPI, 2022-02-11)Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer, and it exhibits a number of clinico-pathological characteristics distinct from the more common invasive ductal carcinoma ... -
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.
Pettitt, SJ; Frankum, JR; Punta, M; Lise, S; Alexander, J; et al. (AMER ASSOC CANCER RESEARCH, 2020-10-01)Reversion mutations in BRCA1 or BRCA2 are associated with resistance to PARP inhibitors and platinum. To better understand the nature of these mutations, we collated, codified, and analyzed more than 300 reversions. This ... -
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Naidoo, K; Wai, PT; Maguire, SL; Daley, F; Haider, S; et al. (AMER ASSOC CANCER RESEARCH, 2018-01-01)Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. ... -
Functional annotation of breast cancer risk loci: current progress and future directions.
Romualdo Cardoso, S; Gillespie, A; Haider, S; Fletcher, O (Springer Science and Business Media LLC, 2022-04-01)Genome-wide association studies coupled with large-scale replication and fine-scale mapping studies have identified more than 150 genomic regions that are associated with breast cancer risk. Here, we review efforts to ... -
Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element.
Baxter, JS; Johnson, N; Tomczyk, K; Gillespie, A; Maguire, S; et al. (CELL PRESS, 2021-07-01)A combination of genetic and functional approaches has identified three independent breast cancer risk loci at 2q35. A recent fine-scale mapping analysis to refine these associations resulted in 1 (signal 1), 5 (signal 2), ... -
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.
Fitzpatrick, A; Iravani, M; Mills, A; Vicente, D; Alaguthurai, T; et al. (Springer Science and Business Media LLC, 2023-11-16)Breast cancer leptomeningeal metastasis (BCLM), where tumour cells grow along the lining of the brain and spinal cord, is a devastating development for patients. Investigating this metastatic site is hampered by difficulty ... -
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
Brough, R; Gulati, A; Haider, S; Kumar, R; Campbell, J; et al. (NATURE PUBLISHING GROUP, 2018-10-25)Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating ... -
Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis.
Jungwirth, U; van Weverwijk, A; Evans, RJ; Jenkins, L; Vicente, D; et al. (NATURE PORTFOLIO, 2021-06-10)Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is ... -
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones, E; Raghunandan, M; Robbez-Masson, L; Magraner-Pardo, L; Alaguthurai, T; et al. (Elsevier BV, 2024-01-19)BACKGROUND: Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple, preclinically validated, mechanisms of resistance have been proposed, ... -
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Zelceski, A; Francica, P; Lingg, L; Mutlu, M; Stok, C; et al. (CELL PRESS, 2023-05-30)The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity ... -
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon, RM; Muirhead, G; Krastev, DB; Adam, J; Morel, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2019-03-01)The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA ... -
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu, D; Robinson, HMR; Alkhatib, O; Boursier, M; Finch, H; et al. (NATURE RESEARCH, 2021-06-17)To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including ... -
Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment.
Stevenson, J; Barrow-McGee, R; Yu, L; Paul, A; Mansfield, D; et al. (NATURE PORTFOLIO, 2021-03-05)In breast cancer (BC), detecting low volumes of axillary lymph node (ALN) metastasis pre-operatively is difficult and novel biomarkers are needed. We recently showed that patient-derived ALNs can be sustained ex-vivo using ...